Kalaris to Present at Stifel 2025 Annual Healthcare Conference
Kalaris (Nasdaq: KLRS) announced that company management will present at the Stifel 2025 Annual Healthcare Conference on Thursday, November 13, 2025 from 3:20–3:50pm ET at the Lotte New York Palace Hotel in New York, NY.
Speakers listed are Andrew Oxtoby, CEO, and Matthew Feinsod, CMO. Management will be available for one-on-one meetings during the conference; interested parties should contact their conference representative to arrange a meeting.
Kalaris (Nasdaq: KLRS) ha annunciato che la direzione aziendale terrà una presentazione alla Stifel 2025 Annual Healthcare Conference il giovedì 13 novembre 2025 dalle 3:20 p.m. alle 3:50 p.m. ET presso l'Hotel Lotte New York Palace a New York, NY.
Gli oratori elencati sono Andrew Oxtoby, CEO e Matthew Feinsod, CMO. La direzione sarà disponibile per incontri one-on-one durante la conferenza; chi fosse interessato dovrebbe contattare il proprio rappresentante della conferenza per concordare un incontro.
Kalaris (Nasdaq: KLRS) anunció que la dirección de la empresa presentará en la Stifel 2025 Annual Healthcare Conference el jueves 13 de noviembre de 2025 desde las 3:20 p.m. a 3:50 p.m. ET en el hotel Lotte New York Palace en Nueva York, NY.
Los ponentes mencionados son Andrew Oxtoby, CEO y Matthew Feinsod, CMO. La dirección estará disponible para reuniones individuales durante la conferencia; las partes interesadas deben ponerse en contacto con su representante de la conferencia para coordinar una reunión.
Kalaris (Nasdaq: KLRS)가 회사 경영진이 Stifel 2025 Annual Healthcare Conference에서 2025년 11월 13일 목요일에 동부 표준시 기준 오후 3시 20분부터 오후 3시 50분까지 뉴욕 NY의 롯데 뉴욕 팰리스 호텔에서 발표할 것이라고 발표했습니다.
발표자는 Andrew Oxtoby, CEO와 Matthew Feinsod, CMO로 나와 있습니다. 경영진은 컨퍼런스 기간 동안 일대일 미팅을 위해 대기할 예정이며, 회의를 주선하려면 컨퍼런스 담당자에게 연락하시면 됩니다.
Kalaris (Nasdaq: KLRS) a annoncé que la direction de l'entreprise présentera lors de la Stifel 2025 Annual Healthcare Conference le jeudi 13 novembre 2025 de 3h20 à 15h50 ET à l'hôtel Lotte New York Palace à New York, NY.
Les intervenants indiqués sont Andrew Oxtoby, PDG et Matthew Feinsod, CMO. La direction sera disponible pour des réunions individuelles pendant la conférence; les parties intéressées devraient contacter leur représentant de la conférence pour organiser une réunion.
Kalaris (Nasdaq: KLRS) kündigte an, dass das Management des Unternehmens auf der Stifel 2025 Annual Healthcare Conference am Donnerstag, dem 13. November 2025 von 3:20–3:50 p.m. ET im Lotte New York Palace Hotel in New York, NY, präsentieren wird.
Als Redner werden Andrew Oxtoby, CEO und Matthew Feinsod, CMO genannt. Das Management wird während der Konferenz für One-on-One-Gespräche zur Verfügung stehen; Interessenten sollten sich an ihren Konferenzvertreter wenden, um ein Treffen zu vereinbaren.
Kalaris (Nasdaq: KLRS) أعلنت أن إدارة الشركة ستقدم عرضًا في مؤتمر Stifel 2025 Annual Healthcare Conference يوم الخميس 13 نوفمبر 2025 من 3:20–3:50 مساءً بتوقيت شرق الولايات المتحدة في فندق لاوت نيويورك بالاس في نيويورك، نيويورك.
المتحدثون المذكورون هم Andrew Oxtoby, CEO، وMatthew Feinsod, CMO. ستكون الإدارة متاحة لعقد اجتماعات فردية خلال المؤتمر؛ يجب على الأطراف المعنية الاتصال بممثل المؤتمر لترتيب اجتماع.
- None.
- None.
PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Stifel 2025 Annual Healthcare Conference.
Details:
- Type: Company presentation
- Speakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical Officer
- Date: Thursday, November 13, 2025
- Time: 3:20 – 3:50pm ET
- Location: Lotte New York Palace Hotel, New York, NY
Kalaris management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.
About Kalaris
Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
For more information, visit www.kalaristx.com.
Kalaris Therapeutics Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
+1 212 915 2577
cdavis@lifesciadvisors.com
ir@kalaristx.com
FAQ
When is Kalaris (KLRS) presenting at the Stifel 2025 Annual Healthcare Conference?
Who will speak for Kalaris (KLRS) at the November 13, 2025 presentation?
Where is the Kalaris (KLRS) presentation being held on November 13, 2025?
Will Kalaris (KLRS) hold one-on-one meetings at the Stifel 2025 conference?
Will Kalaris (KLRS) release clinical data during the Stifel 2025 presentation on November 13, 2025?
How can investors access Kalaris (KLRS) presentation materials from the Stifel 2025 conference?
